Department of Surgery, Gastroenterological Center, Yokohama City University, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.
Department of Gastrointestinal Surgery, Tachikawa Hospital, Tachikawa, Japan.
Gastric Cancer. 2024 Jan;27(1):164-175. doi: 10.1007/s10120-023-01432-y. Epub 2023 Oct 25.
A previous report confirmed the safety of laparoscopy-assisted total and proximal gastrectomies (LATG and LAPG) (JCOG1401). This report demonstrates the 5-year relapse-free survival (RFS) and overall survival (OS) after long-term follow-up to confirm the efficacy of these surgical methods as key secondary endpoints for cStage I gastric cancer.
This study enrolled patients who had histologically proven gastric adenocarcinoma and were diagnosed with clinical T1N0, T1N(+), or T2N0 tumors according to the 14th edition of the Japanese Classification of Gastric Carcinoma (3rd English edition).
Between April 2015 and February 2017, 246 patients were enrolled, although one patient was excluded because of misregistration. Meticulous follow-up was continued for > 5 years for each patient, and the data were analyzed in March 2022. The 5-year RFS was 90.0% (95% confidence interval [CI] 85.5-93.2%), and the 5-year OS was 91.2% (95% CI 86.9-94.2%) in all enrolled patients. Grade 3 or 4 late postoperative complications were detected in 12.7% of patients.
This single-arm study showed that the long-term outcomes of LATG/LAPG for cStage I gastric cancer were acceptable, which is considered one of the standard treatments when performed by experienced surgeons. Trail registration UMIN000017155 ( http://www.umin.ac.jp/ctr/ ).
先前的报告证实了腹腔镜辅助全胃和近端胃切除术(LATG 和 LAPG)的安全性(JCOG1401)。本报告展示了经过长期随访后的 5 年无复发生存率(RFS)和总生存率(OS),以确认这些手术方法作为 cStage I 胃癌的主要次要终点的疗效。
本研究纳入了组织学证实的胃腺癌患者,且根据第 14 版日本胃癌分类(第 3 版英文)诊断为临床 T1N0、T1N(+)或 T2N0 肿瘤。
2015 年 4 月至 2017 年 2 月期间,共纳入 246 例患者,但因登记错误排除了 1 例患者。对每位患者进行了超过 5 年的细致随访,并于 2022 年 3 月进行数据分析。所有入组患者的 5 年 RFS 为 90.0%(95%置信区间 [CI] 85.5-93.2%),5 年 OS 为 91.2%(95% CI 86.9-94.2%)。12.7%的患者出现 3 级或 4 级术后迟发性并发症。
这项单臂研究表明,LATG/LAPG 治疗 cStage I 胃癌的长期疗效是可以接受的,当由经验丰富的外科医生进行操作时,这被认为是一种标准治疗方法。试验注册 UMIN000017155(http://www.umin.ac.jp/ctr/)。